07:00 , May 26, 2014 |  BC Week In Review  |  Financial News

AssureRx completes venture financing

AssureRx Health Inc., Mason, Ohio   Business: Pharmacogenetics   Date completed: 5/21/14   Type: Venture financing   Raised: $7 million   Investors: Sequoia Capital; Claremont Creek Ventures; Mayo Clinic; Cincinnati Children's Hospital Medical Center; CincyTech; Allos Ventures; Four Rivers...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

Anacor management update

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif.   Business: Infectious, Dermatology, Autoimmune   Hired: Chairman Paul Berns as president and CEO, formerly president and CEO of Allos Therapeutics Inc., which Spectrum Pharmaceuticals Inc. acquired; he...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

Belinostat: Final Phase II data

Final data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showed that once-daily IV belinostat led to an ORR of 26%, including a 10% complete...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

Lycera management update

Lycera Corp., Ann Arbor, Mich.   Business: Autoimmune, Transplant   Hired: Bruce Goldsmith as CBO, a newly created position, formerly SVP of corporate development at Allos Therapeutics Inc., which Spectrum Pharmaceuticals Inc. acquired   ...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Belinostat: Additional Phase II data

Topotarget reported additional data from the open-label, international, pivotal Phase II BELIEF (PXD101-CLN-19) trial in 129 patients with relapsed or refractory PTCL showing that once-daily IV belinostat led to an ORR that is "on par"...
02:28 , Mar 6, 2013 |  BC Extra  |  Clinical News

Topotarget gains on belinostat data

Topotarget A/S (CSE:TOPO) gained DKK0.61 (33%) to DKK2.46 on Tuesday after reporting that once-daily IV belinostat led to an objective response rate (ORR) that is "on par" with that of competing drugs Folotyn pralatrexate and...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

ImmunoGen management update

ImmunoGen Inc. (NASDAQ:IMGN), Waltham, Mass.   Business: Cancer   Hired: Charles Morris as EVP and chief development officer, formerly EVP and CMO of Allos Therapeutics Inc., which Spectrum Pharmaceuticals Inc. acquired   ...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Sutro management update

Sutro Biopharma Inc., South San Francisco, Calif.   Business: Biomanufacturing   Hired: Jeremy Bender as CBO, formerly VP of corporate development at Allos Therapeutics Inc., which Spectrum Pharmaceuticals Inc. acquired   ...
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Spectrum Pharmaceuticals cancer news

Spectrum said that the U.S. Patent and Trademark Office (PTO) extended by five years U.S. Patent No. 6,028,071 covering cancer drug Folotyn pralatrexate. The extension postpones the original July 16, 2017, expiration date...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Allos, Spectrum Pharmaceuticals deal

Spectrum completed its acquisition of cancer company Allos for $1.82 per share in cash, or about $194.7 million (see BioCentury, April 9 & Aug. 27). Allos Therapeutics Inc., Westminster, Colo.   Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson,...